Strategies for integrating artificial intelligence into mammography screening programmes: a retrospective simulation analysis.

Autor: Fisches ZV; Vara, Berlin, Germany., Ball M; Vara, Berlin, Germany., Mukama T; Vara, Berlin, Germany. Electronic address: trasias.mukama@vara.ai., Štih V; Vara, Berlin, Germany., Payne NR; Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Hickman SE; Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Department of Radiology, Barts Health NHS Trust, The Royal London Hospital, London, UK., Gilbert FJ; Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK., Bunk S; Vara, Berlin, Germany. Electronic address: stefan.bunk@vara.ai., Leibig C; Vara, Berlin, Germany.

Publikováno v: The Lancet. Digital health [Lancet Digit Health] 2024 Nov; Vol. 6 (11), pp. e803-e814.

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Autor: Wermke M; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.; National Center for Tumor Diseases, Dresden, Germany., Holderried TAW; Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany., Luke JJ; Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA., Alsdorf WH; Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Wetzko K; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany., Andersson BS; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hossain MB; Immatics US, Inc, Houston, Texas, USA., Grund-Gröschke S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Aslan K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Satelli A; Immatics US, Inc, Houston, Texas, USA., Marisetty A; Immatics US, Inc, Houston, Texas, USA., Satam S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kalra M; Immatics US, Inc, Houston, Texas, USA., Hukelmann J; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kursunel MA; Immatics Biotechnologies GmbH, Tuebingen, Germany., Pozo K; Immatics US, Inc, Houston, Texas, USA., Acs A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Backert L; Immatics Biotechnologies GmbH, Tuebingen, Germany., Baumeister M; Immatics Biotechnologies GmbH, Tuebingen, Germany., Bunk S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Wagner C; Immatics Biotechnologies GmbH, Tuebingen, Germany., Schoor O; Immatics Biotechnologies GmbH, Tuebingen, Germany., Mohamed AS; Immatics US, Inc, Houston, Texas, USA., Mayer-Mokler A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany., Krishna D; Immatics US, Inc, Houston, Texas, USA., Walter S; Immatics US, Inc, Houston, Texas, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Britten CM; Immatics Biotechnologies GmbH, Tuebingen, Germany.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 22; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 22.

1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation

Autor: Wermke, M., Ochsenreither, S., Chatterjee, M., Gröpper, S., Häring, M-F., Heudobler, D., Jäger, D., Bleckmann, A., Spoerl, S., Knop, S., Hecker, J.S., Bunk, S., Hilf, N., Hutt, M., Mayer-Mokler, A., Missel, S., Veremchuk, O., Britten, C., Reinhardt, C.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S681-S682

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants.

Autor: Junker D; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Becker M; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Wagner TR; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.; Pharmaceutical Biotechnology, University of Tuebingen, Tuebingen, Germany., Kaiser PD; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Maier S; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Grimm TM; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Griesbaum J; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Marsall P; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Gruber J; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Traenkle B; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Heinzel C; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany., Pinilla YT; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany., Held J; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany., Fendel R; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.; German Center for Infection Research, partner site Tuebingen, Tuebingen, Germany.; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Kreidenweiss A; Institute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany.; German Center for Infection Research, partner site Tuebingen, Tuebingen, Germany.; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Nelde A; Department of Peptide-Based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.; Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, German Cancer Consortium, University Hospital Tuebingen, Tuebingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies,' University of Tuebingen, Tuebingen, Germany., Maringer Y; Department of Peptide-Based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.; Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, German Cancer Consortium, University Hospital Tuebingen, Tuebingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies,' University of Tuebingen, Tuebingen, Germany., Schroeder S; Department of Peptide-Based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University of Tuebingen, Tuebingen, Germany., Walz JS; Department of Peptide-Based Immunotherapy, University of Tuebingen and University Hospital Tuebingen, Tuebingen, Germany.; Department of Internal Medicine, Clinical Collaboration Unit Translational Immunology, German Cancer Consortium, University Hospital Tuebingen, Tuebingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies,' University of Tuebingen, Tuebingen, Germany., Althaus K; Center for Clinical Transfusion Medicine, Tuebingen, Germany.; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany., Uzun G; Center for Clinical Transfusion Medicine, Tuebingen, Germany., Mikus M; Center for Clinical Transfusion Medicine, Tuebingen, Germany., Bakchoul T; Center for Clinical Transfusion Medicine, Tuebingen, Germany.; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Tuebingen, Germany., Schenke-Layland K; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.; Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany.; Department for Medical Technologies and Regenerative Medicine, Institute of Biomedical Engineering, University of Tuebingen, Tuebingen, Germany.; Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA., Bunk S; Infectious Diseases, Department of Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany., Haeberle H; Department of Anaesthesiology and Intensive Care Medicine, University Hospital Tuebingen, Tuebingen, Germany., Göpel S; German Center for Infection Research, partner site Tuebingen, Tuebingen, Germany.; Infectious Diseases, Department of Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany., Bitzer M; Infectious Diseases, Department of Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany.; Center for Personalized Medicine, University of Tuebingen, Tuebingen, Germany., Renk H; University Children's Hospital, Tuebingen, Germany., Remppis J; University Children's Hospital, Tuebingen, Germany., Engel C; University Children's Hospital, Tuebingen, Germany.; Center for Pediatric Clinical Studies, University Hospital Tuebingen, Tuebingen, Germany., Franz AR; University Children's Hospital, Tuebingen, Germany.; Center for Pediatric Clinical Studies, University Hospital Tuebingen, Tuebingen, Germany., Harries M; Helmholtz Centre for Infection Research, Braunschweig, Germany., Kessel B; Helmholtz Centre for Infection Research, Braunschweig, Germany., Lange B; Helmholtz Centre for Infection Research, Braunschweig, Germany., Strengert M; Helmholtz Centre for Infection Research, Braunschweig, Germany.; TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany., Krause G; Helmholtz Centre for Infection Research, Braunschweig, Germany.; TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany., Zeck A; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Rothbauer U; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.; Pharmaceutical Biotechnology, University of Tuebingen, Tuebingen, Germany., Dulovic A; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany., Schneiderhan-Marra N; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Feb 08; Vol. 76 (3), pp. e240-e249.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.